StockData
INDPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Indaptus Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.73+0.10 (+3.80%)

Close on Oct 19, 2026

Market cap
$317.04M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 13, 2026Before market open–$-0.02–
Q1 FY2026
Ended Mar 31, 2026
May 15, 2026Before market open–$-0.23–
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025Before market open–––
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025Before market open–$-9.09–
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025Before market open–$-0.32–
Q4 FY2024
Ended Dec 31, 2024
Mar 13, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open–$-0.32–
Q2 FY2024
Ended Jun 30, 2024
Aug 12, 2024Before market open–$-0.47–
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024Before market open–$-0.45–
Q4 FY2023
Ended Dec 31, 2023
Mar 13, 2024Before market open–––
Q3 FY2023
Ended Sep 30, 2023
Nov 6, 2023After market close–$-0.47–

Press releases

Announcements Indaptus Therapeutics filed with the SEC